Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 5/2002

01-06-2002 | Originales

A comparative study of HER2/neu amplification and overexpression using fluorescencein situ hybridization (FISH) and immunohistochemistry (IHC) in 101 breast cancer patients

Authors: Marta Salido, Francesc Solé, Ignasi Tusquets, Josep M. Corominas, Blanca Espinet, MaLluïsa Mariñoso, Teresa Baró, MaCarmen Vela, Xavier Fabregat, Sergi Serrano

Published in: Clinical and Translational Oncology | Issue 5/2002

Login to get access
Metadata
Title
A comparative study of HER2/neu amplification and overexpression using fluorescencein situ hybridization (FISH) and immunohistochemistry (IHC) in 101 breast cancer patients
Authors
Marta Salido
Francesc Solé
Ignasi Tusquets
Josep M. Corominas
Blanca Espinet
MaLluïsa Mariñoso
Teresa Baró
MaCarmen Vela
Xavier Fabregat
Sergi Serrano
Publication date
01-06-2002
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 5/2002
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/BF02732510

Other articles of this Issue 5/2002

Clinical and Translational Oncology 5/2002 Go to the issue

Editorial

Prostate cancer: the great unknown

Announcement

Información

Originales

Factors involved in morbidity and mortality of total gastrectomy for gastric cancer

Originales

Cisplatin-based chemotherapy and hyperfractionated radiotherapy for stage III non-small cell lung cancer: survival and patterns of failure after long follow-up

Originales

Respuesta terapéutica a gemcitabina en cáncer de mama avanzado en relación con factores immunohistoquímicos

Revisiones

Aspectos clínicos de la biología molecular del cáncer de próstata
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits